Paxman, the leading global expert and supplier in scalp cooling for cancer chemotherapy patients, has been granted Investigational Device Exemption (IDE) Approval by the U.S. Food and Drug Administration FDA ahead of a multi-centre, randomized trial of the patented Paxman scalp cooling system for the prevention of chemotherapy induced alopecia.
Paxman, the leading global expert and supplier in scalp cooling for cancer chemotherapy patients, has been granted Investigational Device Exemption (IDE) Approval by the U.S. Food and Drug Administration FDA ahead of a multi-centre, randomized trial of the patented Paxman scalp cooling system for the prevention of chemotherapy induced alopecia.
First results from a phase III clinical trial of the combination drug, T-DM1, show that it significantly improves the length of time before the disease worsens in women with advanced HER2 positive breast cancer whose cancer has recurred or progressed despite previous treatments, including trastuzumab and lapatinib...
An experimental new drug by Pfizer has been proven to eliminate progression of an incurable form of breast cancer for over two years, according to new research presented at the San Antonio Breast Cancer Symposium. Patients were given the medicine, called PD 0332991, with Novartis (NOVN) AG's Femara. The findings reveal no tumor advancement for a median of 26.1 months, compared with 7...
